Frontlight ResearchEarly access
Active, not recruitingNo phase
Delirium in Children Undergoing Stem Cell Transplantation
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- Boston, Memphis, New York, Philadelphia, and San Francisco, United StatesSee the 5 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 1,040 people enrolled
- Started
- 12 Jul 2021
- Expected to end
- 31 Jul 2027
- Type of study
- Observational
- Treatments tested
- Daily screening for delirium
- Record updated
- 23 October 2026
Who can take part
- Age
- Up to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age 0-21 years old
- Admitted for purpose of stem cell transplant
Who cannot take part
- Admitted for reason other than stem cell transplant (example: late post-transplant complications)
- Age >21 years old
Where in United States
Also in 1 other country, 1 site
- Dana Farber Cancer CenterBoston, United States
- St. Jude Children's Research HospitalMemphis, United States
- Weill Cornell Medical CollegeNew York, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- University of California San FranciscoSan Francisco, United States
About the trial
What the trial wants to find out
Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.
The group in the trial
- Pediatric Stem Cell Transplant Patients
A consecutive cohort of children admitted to the hospital for stem cell transplantation
Treatment: Daily screening for delirium
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Delirium in Children Undergoing Stem Cell Transplantation: Epidemiology and Outcomes
- Record updated
- 23 October 2026